



Centre de Neurosciences Psychiatriques

CNP SEMINAR

ANNOUNCEMENT

Thursday, August 25th 2022, 11 am

'The Glutamate Hypothesis of Schizophrenia – Still Viable?'

Prof. Larry Kegeles

Professor of clinical psychiatry at Columbia University Irving Medical Center, specialist of MR spectroscopy in schizophrenia

This talk will briefly review the glutamate hypothesis of schizophrenia and some of the failed late-stage clinical trials of Glu system-based therapeutics. Recent work on validation of biomarkers of the Glu system and their response to Glu agents will be summarized, along with implications regarding the earlier failed trials. Ongoing and planned testing of Glu agents suggested by these biomarker studies will be outlined.

Invited by paul.klauser@unil.ch and kim.do@chuv.ch

Selected recent publications:

- *Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.*

Kinon BJ et al., Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016.

- *Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.*

Javitt DC et al., JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572.

- *Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacobOLD in healthy volunteers.*

Kantrowitz JT et al., Neuropsychopharmacology. 2020 Oct;45(11):1842-1850. doi: 10.1038/s41386-020-0706-z

**Salle de séminaire, 1^{er} étage CNP
Hôpital Psychiatrique de Cery-Site de Cery, CH-1008 Prilly-Lausanne**

Link for videoconference <https://chuv.webex.com/chuv/j.php?MTID=m7b00630fa3d7b55fd3a6491a10e59ce3>